(Q38781439)

6 September 2017

title

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma (English)

1 reference

6 September 2017

A Bensussan

11

0 references

author name string

M Battistella

1

1 reference

6 September 2017

A Janin

2

1 reference

6 September 2017

F Jean-Louis

3

1 reference

6 September 2017

C Collomb

4

1 reference

6 September 2017

C Leboeuf

5

1 reference

6 September 2017

H Sicard

6

1 reference

6 September 2017

C Bonnafous

7

1 reference

6 September 2017

A Dujardin

8

1 reference

6 September 2017

C Ram-Wolff

9

1 reference

6 September 2017

M E Kadin

10

1 reference

6 September 2017

M Bagot

12

1 reference

6 September 2017

L Michel

13

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 April 2016

1 reference

British Journal of Dermatology

6 September 2017

published in

1 reference

6 September 2017

volume

175

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

325-333

1 reference

Function and specificity of human natural killer cell receptors

6 September 2017

cites work

1 reference

CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.

21 January 2018

1 reference

CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.

21 January 2018

1 reference

CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.

21 January 2018

1 reference

IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.

21 January 2018

1 reference

WHO-EORTC classification for cutaneous lymphomas

21 January 2018

1 reference

Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome

21 January 2018

1 reference

Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.

21 January 2018

1 reference

Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.

21 January 2018

1 reference

Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis

21 January 2018

1 reference

NKp46-specific expression on skin-resident CD4(+) lymphocytes in mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

21 January 2018

1 reference

Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports

21 January 2018

1 reference

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJD.14626

1 reference

6 September 2017

1 reference